Medical and non‐medical predictors of initiating long‐term use of proton pump inhibitors: a nationwide cohort study of first‐time users during a 10‐year period

Haastrup, Peter; Paulsen, Maja Skov; Christensen, René dePont; Søndergaard, Jens; Hansen, Jane Møller; Jarbøl, Dorte Ejg

doi:10.1111/apt.13649

Cited by 44 publications

(35 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, giving PPI prevents gastric mucosal injuries from the use of low‐dose aspirin and non‐steroidal anti‐inflammatory drugs (NSAIDs) . Therefore, PPI are widely used, and the number of PPI users has been increasing . Several studies have confirmed high rates of long‐term use of PPI …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gastric mucosal cracked and cobblestone‐like changes resulting from proton pump inhibitor use

Miyamoto

Kato

Tsuda

et al. 2017

Digestive Endoscopy

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Therefore, PPI are widely used, and the number of PPI users has been increasing . Several studies have confirmed high rates of long‐term use of PPI …”

Section: Introductionmentioning

confidence: 99%

Gastric mucosal cracked and cobblestone‐like changes resulting from proton pump inhibitor use

Miyamoto

Kato

Tsuda

et al. 2017

Digestive Endoscopy

View full text Add to dashboard Cite

show abstract

“…PPIs are widely available for acid-related disorders such as gastric or duodenal ulcers and gastroesophageal reflux disease. The use of PPIs is increasing [1]. In addition, high rates of long-term PPI use are reported [1,2].…”

Section: Introductionmentioning

confidence: 99%

“…The use of PPIs is increasing [1]. In addition, high rates of long-term PPI use are reported [1,2]. The long-term use of PPIs is related to some side effects such as enteric infections [3] and fractures [4].…”

Section: Introductionmentioning

confidence: 99%

Endoscopic ultrasonography features of gastric mucosal cobblestone-like changes from a proton-pump inhibitor

Miyamoto

Kudo

Kato

et al. 2017

Clin J Gastroenterol

View full text Add to dashboard Cite

A 68-year-old man with no symptoms presented to Hokkaido University Hospital for esophagogastroduodenoscopy screening. He had a history of Helicobacter pylori eradication. Initial esophagogastroduodenoscopy showed no gastric cobblestone-like mucosa or gastric cracked mucosa. After 1 year, he received esomeprazole (20 mg) once daily for heartburn at another hospital.Esophagogastroduodenoscopy was performed after 2 years of esomeprazole administration. Endoscopic findings showed that after H. pylori eradication, according to the Kyoto classification, gastric cobblestone-like mucosa presented in the gastric body area. Dilation of the oval crypt opening and intervening part in the gastric cobblestone-like mucosa was detected by endoscopy with narrow band imaging. Endoscopic ultrasonography revealed a thick gastric second layer and sporadic small a-echoic lesions in the low-echoic thickened second layer in the gastric cobblestone-like mucosa. The gastric cobblestone-like mucosa biopsy specimen showed parietal cell protrusions and oxyntic gland dilatations.Recently, we reported that gastric mucosal changes such as gastric cracked mucosa and gastric cobblestone-like mucosa were caused by proton-pump inhibitors; however, the gastric cobblestone-like mucosa was not examined by endoscopic ultrasonography. In this case, endoscopic ultrasonography findings suggested that oxyntic gland dilatations caused the elevated gastric mucosa, such as gastric cobblestone-like mucosa, from the use of proton-pump inhibitors.3

show abstract

“…В режиме безре-цептурного отпуска, т.е. приема не более 2 нед., для купиро-вания изжоги, возникающей два раза в неделю, ИПП, в частности декслансопразол, рассматриваются как самый безопасный класс препаратов [2,18,26]. Гибкость режима приема может способствовать повышению удобства для пациента и увеличению его приверженности терапии.…”

unclassified

The strategy for choosing a new-generation proton pump inhibitor dexlansoprazole in the treatment of gastroesophageal reflux disease

Topchiy¹,

Топорков²

2018

Med. sov.

View full text Add to dashboard Cite

N. V.TOPCHIY, PhD in medicine, A.S.TOPORKOV, PhD in medicine Russian Medical Academy of Continuing Postgraduate Education; Association of General Practitioners (Family Physicians) of the Russian Federation Russian Gastroenterological Association THE STRATEGY FOR CHOOSING A NEW-GENERATION PROTON PUMP INHIBITOR DEXLANSOPRAZOLE IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASEThe flexible dosage form combined with the increased maintenance of a therapeutic dextensoprazole concentration in plasma with a modified release and prolonged inhibition of acid secretion after administration of the drug suggests that dexlansoprozole has several advantages for patients with acid-dependent diseases. The pharmacokinetic profile of dexlansoprazole is characterized by two Tmax peaks in 1-2 and 4-5 hours after administrating the drug and ensures a stable concentration of it in the blood. The efficacy of dexlansoprozole in the treatment of various forms of gastroesophageal reflux disease has been confirmed by several randomized controlled clinical trials.

show abstract

Medical and non‐medical predictors of initiating long‐term use of proton pump inhibitors: a nationwide cohort study of first‐time users during a 10‐year period

Cited by 44 publications

References 35 publications

Gastric mucosal cracked and cobblestone‐like changes resulting from proton pump inhibitor use

Gastric mucosal cracked and cobblestone‐like changes resulting from proton pump inhibitor use

Endoscopic ultrasonography features of gastric mucosal cobblestone-like changes from a proton-pump inhibitor

The strategy for choosing a new-generation proton pump inhibitor dexlansoprazole in the treatment of gastroesophageal reflux disease

Contact Info

Product

Resources

About